In gastric cancer, tumor MET expression is associated with tumor invasiveness, metastasis, and disease stage. Rilotumumab is an investigational, fully human, IgG2 monoclonal antibody that targets hepatocyte growth factor, the only known ligand for the MET receptor. In a randomized, placebo-controlled, phase 2 study, rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) compared with ECX alone showed trends toward improved survival in patients with on April 14, 2017.
INTRODUCTION
Worldwide, gastric cancer is the second leading cause of cancer-related deaths, and its incidence and mortality are higher in developing countries (1) . The 5-year survival rate for gastric cancer remains low at approximately 25% (2) .
Hepatocyte growth factor (HGF) or scatter factor is the only known ligand for the MET proto-oncogene, a tyrosine kinase receptor activated upon HGF binding (3) . Together, HGF/MET comprises a well-characterized ligand/receptor complex involved in multiple cellular functions, including proliferation and survival (3) . The HGF/MET pathway is also necessary for tissue repair and regeneration (3) . Abnormal signalling in this pathway has been directly implicated in tumor growth and progression in a wide variety of human cancer types, including gastric cancer, making this a promising pathway for developing new targeted anticancer therapies (4, 5) . Elevated levels of tumor MET have been associated with disease progression and poor prognosis in patients with gastric cancer (6) (7) (8) (9) (10) .
Rilotumumab (AMG 102) is a fully human monoclonal antibody (IgG2) that binds to human HGF with high affinity (dissociation constant, K D = 6 ng/mL) and neutralizes HGF (11) .
Rilotumumab inhibited tumor growth, induced tumor regression, increased apoptosis, and decreased cell proliferation in human xenograft models of cancer (12) and has demonstrated manageable toxicities in clinical studies (13) (14) (15) . In humans, rilotumumab evidenced linear and time-independent pharmacokinetics (PK) up to 20 mg/kg administered intravenously (IV) every 2 weeks (Q2W) and 15 mg/kg every 3 weeks (Q3W) (16) . Notably, rilotumumab clearance was not affected by baseline tumor HGF and MET levels, hepatic and renal functions, and drug-drug interactions with other anticancer agents (16) . In a placebo-controlled, randomized phase 2 study in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer (ClinicalTrials.gov identifier: NCT00719550), 7.5 or 15 mg/kg rilotumumab administered Q3W in combination with epirubicin, cisplatin, and capecitabine (ECX) showed trends toward improved progression-free survival (PFS) and overall survival (OS), and a stronger rilotumumab effect was observed in a subset of patients with MET-positive tumor expression, as determined by an immunohistochemistry assay that used the MET4 monoclonal antibody (MET IHC pharmDx TM kit; Dako North America; Carpinteria, CA) (17) .
Drug-disease models are powerful tools to analyze early clinical data, optimize dosing schedule, and scale across patient populations and drug development phases (eg, phase 2 to phase 3) (18, 19) . In order to develop a drug-disease model for gastric/GEJ cancer and quantitatively establish the relationship among chemotherapy dosing, rilotumumab serum concentrations, and their anticancer effects, we developed a modeling framework that includes a longitudinal tumor growth (TG) and OS model. The TG model describes the inhibitory effect of ECX and ECX plus rilotumumab on tumor size and serves as an input for the OS model, which incorporates prognostic and predictive factors for patients with gastric/GEJ cancer. We used this approach to retrospectively evaluate patients from the phase 2 gastric/GEJ cancer study (17) . Our objective was to predict the relationship between rilotumumab dose and OS and then predict the OS outcome of a study evaluating rilotumumab in combination with ECX versus ECX alone in MET-positive gastric/GEJ cancer (RILOMET-1; ClinicalTrials.gov identifier: NCT01697072).
Research. 
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PATIENTS AND METHODS
Clinical Data and Assessments
Rilotumumab serum concentrations, tumor size measurements, and OS data from a phase 2 clinical study in patients with locally advanced or metastatic gastric/GEJ cancer were used in this analysis. Briefly, eligible patients received ECX (epirubicin 50 mg/m 2 IV on day 1, cisplatin 60 mg/m 2 IV on day 1, and capecitabine 625 mg/m 2 orally twice daily on days 1-21, respectively) and were randomized 1:1:1 to receive 7.5 mg/kg rilotumumab, 15 mg/kg rilotumumab, or placebo Q3W. In all cases, rilotumumab was administered as an IV infusion over 60 minutes for the first dose and 30 minutes for subsequent doses if it was well tolerated. Additional details of this clinical study have been reported elsewhere (17) .
Serum samples for the measurement of rilotumumab concentrations were collected predose and postdose on day 1 of cycles 1, 3, 5, and 7 and at the safety follow-up visit. Rilotumumab concentrations were determined by an enzyme-linked immunosorbent assay using recombinant human HGF for the capture reagent and a biotinylated polyclonal rabbit anti-rilotumumab antibody for detection, as previously reported (14, 20) . Tumor size was assessed by computed tomography or magnetic resonance imaging at screening and every 6 weeks (7 days) and was computed as the sum of the longest diameters of target lesions according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.0. OS time was determined as the time from randomization to death from any cause. For OS, patient follow up was censored at the date last known to be alive. Tumor MET expression was measured in archival tumor samples by immunohistochemistry as described elsewhere (17) . Patients were divided into MET-positive and MET-negative groups based on tumor MET membrane expression, per two definitions (≥25% or ≥50%) as previously described (17) .
Model Development
The integrated model (Figure 1 ) was developed using the nonlinear mixed effects modeling (NONMEM) software Version 7.2.0 (ICON Development Solutions, Ellicott City, MD) with the Intel Fortran 11.1 compiler. Graphical data visualization, evaluation of NONMEM outputs, construction of goodness-of-fit plots, and graphical model comparisons were conducted using SPlus Version 8.2 (TIBCO Software Inc., Palo Alto, CA).
Pharmacokinetic Model. Individual PK parameters were estimated from the observed rilotumumab serum concentrations and the population PK model that was previously developed (16) , which was based on an open two-compartment disposition model. The inter-individual variability (IIV) in the model parameters was assumed to follow a log-normal distribution, and a proportional random error model was used to quantify the residual variability. The effect of tumor MET expression on PK parameters was formally explored using the statistical criteria, as previously described (21) . Individual PK parameters were used to predict the individual rilotumumab serum concentrations over time, which in turn were used as an input function for the TG model following the sequential process, as described elsewhere (22) .
Tumor Growth Model. In the absence of any treatment, the tumor size was assumed to grow exponentially at a first-order rate, k g (23) . Treatment with ECX was assumed to simulate the first-order tumor-cell death rate, k d . Since no PK data for ECX were available, a "kinetics of drug action" model was used to quantify the effect of ECX on k d , which was driven by the first- order rate constant, k PD . Furthermore, the effect of ECX on k d was assumed to decrease over time, probably due to a resistance phenomenon, and was determined by a first-order process characterized by k res,ECX . The differential equations describing the time course of tumor size in patients treated with ECX were as follows:
where
In these equations, TS represented the tumor size at time t, and TS 0 was the estimated baseline tumor size. The addition of rilotumumab resulted in an inhibitory effect on k g , which depended on the rilotumumab serum concentration and was set to 0 in the placebo group. The maximum k g inhibition was assumed to be 100%, and the rilotumumab concentration that provided half maximal k g inhibition, EC 50 , was estimated directly from the tumor size data. Rilotumumab resistance effects were similarly incorporated into the model to describe the increase in tumor size apparent in some patients receiving ECX and rilotumumab and were determined by the firstorder rate constant, k res,R . Consequently, Equation 1 was modified to Equation 3 in order to describe the combined effect of ECX and rilotumumab:
Equation 3
Research. IIV in k g , k d , k res,ECX was described by an exponential error model, while IIV in TS 0 was modeled through a semiparametric logit transformation (24) . A proportional random error model was used to describe the residual variability associated with the tumor size measurements. The effect of tumor MET expression on TG model parameters was also formally tested as a covariate.
OS Model. A parametric OS model was developed to describe the survival time (T) distribution. Normal, lognormal, Weibull, logistic, log-logistic, exponential, or Gompertz probability density functions were evaluated, and the likelihood ratio test was used to select the best probability density functions to describe the OS data. In addition, improvement of the model by the inclusion of MET expression as a prognostic and/or predictive factor and treatmentrelated factors (steady-state rilotumumab exposure and predicted reduction in tumor size at varying study weeks [ie, 6, 12, 18, 24, or 30]) on absolute baseline hazard was evaluated.
Model Selection and Evaluation
The improvement of the fit obtained for each nested model was assessed by the likelihood ratio test. The precision and the correlation in parameter estimates and the examination of diagnostic plots and visual predictive checks (VPCs) were also used to evaluate each candidate model (25, 26) . In addition, the shrinkage, reduction in the IIV and residual variability, and normalized prediction distribution errors (NPDEs) in the PK and TG models were also assessed (27) . Additionally, non-parametric bootstrap of the TG and OS models was also performed as internal validation (28) .
Model-Based Simulations
Research. Model-based Monte Carlo simulations were conducted to explore the effect of the rilotumumab Q3W dose (7.5, 10, 15, 20 mg/kg) on the OS hazard ratio of a virtual study with the same characteristics as a phase 3 trial in patients with advanced MET-positive (≥25% membrane staining) gastric/GEJ cancer (NCT01697072). In this virtual study, 450 patients were randomized 1:1 to ECX alone or rilotumumab plus ECX, as previously described (32) . The virtual study was replicated 1000 times per each dose level evaluated using the PK, tumor size and parametric OS model previously described. The rate of patient enrollment was simulated to mimic the observed patient enrollment in the phase 2 study. The simulations accounted for censored data by using a dropout model, which was based on an exponential hazard for the first 200 days after enrollment, followed by a Weibull hazard until the end of study. The dropout model was necessary to account for the differential dropout observed in the phase 2 study, which is likely to similarly occur during the phase 3 study. The virtual trials were stopped once the target number of events (n = 316) was reached. Virtual patients who dropped out or were alive at the time of study termination were considered as censored. The OS for each study arm and replicate as well as the hazard ratio of each virtual trial replicate were computed and then summarized across replicates. 
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RESULTS
Pharmacokinetic Model
A total of 390 serum concentrations from 88 patients with gastric/GEJ cancer were used to 
Tumor Growth Model
In total, 504 tumor size measurements from 120 patients were available to develop the TG model. Eleven patients (two in the 7.5 mg/kg group, five in the 15 mg/kg group, and four in the placebo group) only had available tumor size data at screening and were excluded from the analysis. The TG model was suitable to describe the time course of the tumor size in patients with gastric/GEJ cancer following IV administration of 7.5 and 15 mg/kg rilotumumab in combination with ECX or ECX alone. The final model parameter estimates and their relative standard error (RSE) are presented in Table 1 . If left untreated, the gastric/GEJ tumor was assumed to grow exponentially, and approximately 16 months were needed to double its size.
The half-life associated with the effect of ECX administration, which provides an assessment of the duration of ECX effect, was estimated and fixed to 331 hours (approximately 2 weeks) based on data from patients receiving placebo plus ECX. In the absence of ECX resistance, Q3W dosing of ECX resulted in 50% average tumor shrinkage in approximately 2 months. However, the effect of ECX on k d was reduced by 50% every 1.4 months. A linear function was sufficient in describing the ECX effect on the stimulation of k d and attempts made to characterize the ECX effect as an E max or log-linear model failed as the parameters could not be reliably estimated, probably because all patients received the same dosing regimen, and the maximum ECX effect was not achieved.
The typical value of rilotumumab EC 50 was estimated to be 6.71 g/mL. The mean (SD) rilotumumab trough levels at steady state (C minss ) were 72.7 (34.7) g/mL and 171 (80) g/mL following the 7.5 and 15 mg/kg doses, respectively. At these concentrations, the mean (SD) (Table 1) , except EC 50 (RSE 227%) and k res,R (RSE 72%), which was probably due to the fact that the two rilotumumab dose levels evaluated were well above the EC 50, and the maximum follow-up time was 25.5 months, which is comparable to the half-life associated with the rilotumumab resistance effect. However, the goodness-of-fit plots showed that observations were randomly distributed around the identity 
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The maximal OS follow-up time was 765 days (~25.5 months), and several MET-positive patients displayed survival times greater than 18 months. Based on the likelihood ratio test, the Weibull model was the best probability density function to parametrically describe the OS data (Table 2 ). Tumor MET expression was found to be associated with the scale parameter () of the Weibull model (P = 0.003). A 71.6% increase in  was observed in patients with MET-positive status (≥25% membrane staining) relative to patients with MET-negative status, indicating that positive MET expression was a negative prognostic factor for OS as was expected given the observation that median OS in the ECX arm was longer in MET-negative patients (17) .
Furthermore the predicted tumor size at 6 months was found to be a significant predictive factor of OS (P = 0.009) and was better than the predicted tumor size at earlier or later time points. On average, an 18% reduction of the hazard was achieved after 25% reduction in tumor size at 6 months.
There was a direct effect of rilotumumab C minss on OS hazard (P = 0.002). The effect was quantified with a step function, parameterized as a sigmoid E max function with a fixed high Hillfactor, where the estimated maximum reduction of the OS hazard was 65% and the rilotumumab C minss providing half-maximal reduction (EC 50 ) was 71.5 and 202 g/mL for a MET-positive and MET-negative patient, respectively. Based on the limited number of MET-positive patients in the 7.5 (n = 16) and 15 mg/kg (n = 11) dose groups, positive MET expression was also found to have a predictive effect on rilotumumab treatment outcome on OS and was significantly associated with the EC 50Cminss (P = 0.0008). The analysis was repeated using an alternative definition of MET positivity (≥50% membrane staining), and results were similar (data not shown). The equations for the OS model are presented below. MET  is the effect of MET-positive status (≥25% membrane staining) on ; R is the effect of rilotumumab treatment on the hazard; E max is the maximum effect of rilotumumab treatment on the hazard; C minss is the steady-state trough concentration of rilotumumab; EC 50Cminss is the rilotumumab concentration providing 50% of the maximum effect of rilotumumab treatment;
MET
Cminss is the effect of MET-positive status on EC 50Cminss and hill is the Hill-factor for the sigmoid E max function. All OS model parameters were well estimated, and the VPC ( Rilotumumab exhibited linear and time-independent PK, which was adequately described by a two-compartment disposition model over a dose range of 0.5-20 mg/kg (16) . Following Q3W administration, steady state was reached at 4 months with a two-fold accumulation factor.
The estimated systemic CL and V c were comparable with endogenous IgGs, as reported in a previous population PK analysis (16) . Consistent with previous results, our findings confirmed that no covariates, including tumor MET expression or the administration of ECX, affected 
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was the major contributor to tumor reduction and with limited further tumor reduction due to saturation of tumor growth inhibition at the rilotumumab doses tested (~30% decrease from baseline for ECX alone versus ~40% for ECX plus 7.5 or 15 mg/kg rilotumumab), it was difficult to further discern any apoptotic effect of rilotumumab, as previously reported (12) , or the relationship between MET-expression and rilotumumab-related TG model parameters.
The joint effect of ECX and rilotumumab on tumor reduction further contributes to the decrease of the OS hazard. The change in tumor size from baseline at week 6 or 8 has been proposed to capture the treatment effect and predict survival in several tumor types (30) (31) (32) (33) .
However, it has been postulated that these times might not fully capture the treatment effect, particularly for the new targeted therapies. In fact, in the present analysis, the tumor size reduction at 24 weeks was the best OS predictive factor among the tumor sizes at other time points. However, the inclusion of predicted reduction in tumor size at 24 weeks in the model is problematic, as the majority of patients were not dosed with rilotumumab for 24 weeks nor was the tumor size assessed at 24 weeks. Thus, while reduction in tumor size at week 24 was most predictive, it may not be feasible to observe in patients. Additionally, the influence of tumor size on OS was based on a predicted rather than observed tumor assessment. Higher rilotumumab concentrations (C minss >71.5 g/mL) had an additional predictive value of the OS hazard in MET-positive patients. The effect of MET expression on EC 50Cminss , with approximately a threefold higher EC 50Cminss in MET-negative patients, suggests that patients with positive MET expression are more sensitive or responsive to rilotumumab treatment than patients with negative MET expression, as previously observed (17) . Interestingly, tumor MET expression appeared to be both prognostic and predictive of OS in patients with gastric/GEJ cancer who were treated Furthermore, the probability of success of a phase 3 trial using rilotumumab 15 mg/kg Q3W is >90% at the pre-specified sample size, with the same patient population and MET positivity observed in the phase 2 study. This new technology should be applied at the end of phase 2 studies in order to optimize the phase 3 study design, maximize its probability of success, and However, as it is often the case at the end of phase 2 development for novel therapeutics in cancer patients, there is limited information for both model development and evaluation. In this analysis, a single phase 2 clinical study in gastric cancer patients was used to develop and evaluate the OS model. Additionally, key components of the OS model (i.e., rilotumumab steady state exposure, predicted tumor size at week 24, and MET status) were not available for all subjects in the phase 2 study, thus, the OS model incorporates a subset of the phase 2 population which may not adequately represent the overall gastric cancer population which will enrol in the phase 3 study.
Differences in the study characteristics, specifically, inclusion/exclusion criteria, prior treatment, changes in co-medications or standard of care, between the phase 2 and phase 3 studies may also impact the validity of the model based predictions for the outcome of the phase 3 study. Thus, evaluation of the model against and updating with data from subsequent trials with rilotumumab in gastric cancer patients is needed to confirm its validity.
In summary, the current PK and pharmacodynamic assessment revealed that rilotumumab Research. 
